Cancer Therapy
Bendamustine-plus-rituximab is an effective lymphoma treatment
Published in Hepatitis Weekly, August 1st, 2005
According to a study from Germany, "The aim of this multicenter-study was to evaluate the progression-free survival, response rate, and toxicity of the combination of bendamustine and rituximab in patients with mantle cell or low-grade lymphomas in first to third relapse or refractory to previous treatment. A total of 245 courses (median, 4 courses per patient) were administered to 63 patients."
"Bendamustine was given at a dose of 90 mg/m2 as a 30-minute infusion on days 1 and 2, combined with 375 mg/m2 rituximab on day 1, for a maximum of 4 cycles every 4...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-08-01)
More Articles from Hepatitis Weekly
- Cancer Detection
The ANN/TM-GTP index accurately predicts recurrent liver cancer - Hepatitis C Therapy
Hepatitis C patients without spontaneous clearance respond to PEG-interferon - Oncology
Oral contraceptive use helps women survive liver cancer - Pediatric Hepatology
Lamivudine impairs glucose metabolism in children with chronic hepatitis B - Virology
Liver-specific interferon gamma expression controls hepatitis B in mice - Addiction Medicine
New findings in the area of addiction medicine detailed - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
